Grade 3/4 adverse events Minimum 24 weeks, maximum 100 weeks [clinicaltrials_resource:a94b0d4bb4374b7567af5573902f6b9c]
The primary analysis will be the difference in proportions ever experiencing one or more grade 3 or 4 adverse events (AEs) after substudy randomisation, with non-inferiority demonstrated if the upper limit of the 90% confidence interval around the risk difference(Group 2 - Group 1) lies below +20%.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Grade 3/4 adverse events Minimum 24 weeks, maximum 100 weeks [clinicaltrials_resource:a94b0d4bb4374b7567af5573902f6b9c]
The primary analysis will be the difference in proportions ever experiencing one or more grade 3 or 4 adverse events (AEs) after substudy randomisation, with non-inferiority demonstrated if the upper limit of the 90% confidence interval around the risk difference(Group 2 - Group 1) lies below +20%.
Bio2RDF identifier
a94b0d4bb4374b7567af5573902f6b9c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a94b0d4bb4374b7567af5573902f6b9c
measure [clinicaltrials_vocabulary:measure]
Grade 3/4 adverse events
time frame [clinicaltrials_vocabulary:time-frame]
Minimum 24 weeks, maximum 100 weeks
description
The primary analysis will be t ...... 2 - Group 1) lies below +20%.
identifier
clinicaltrials_resource:a94b0d4bb4374b7567af5573902f6b9c
title
Grade 3/4 adverse events Minimum 24 weeks, maximum 100 weeks
@en
type
label
Grade 3/4 adverse events Minim ...... b0d4bb4374b7567af5573902f6b9c]
@en